α-Linoleoyl-β-linolenoyl-α'-oleoyl-triglycerid | 97901-05-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: α-Linoleoyl-β-linolenoyl-α'-oleoyl-triglycerid
• 英文别名: 1-Oleoyloxy-2-α-linolenoyloxy-3-linoleoyloxy-propan；[3-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropyl] (Z)-octadec-9-enoate
• CAS: 97901-05-8
• 化学式: C₅₇H₉₈O₆
• 分子量: 879.402
• InChiKey: REIXCKVDZDXOTL-MDYNWYMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  20.3
• 重原子数：
  63
• 可旋转键数：
  50
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  甘油三油酸酯 、 甘油三亚油酸酯 、 三亚麻精 在 sodium methylate 作用下， 以 正己烷 为溶剂， 反应 0.5h， 生成 1-O-linolenoyl-2-O-linoleoyl-3-O-oleoyl glycerol 、 soybean oil 、 α-Linoleoyl-β-linolenoyl-α'-oleoyl-triglycerid
  参考文献：
  名称：

  Regioisomeric Characterization of Triacylglycerols Using Silver-Ion HPLC/MS and Randomization Synthesis of Standards

  摘要：

  银离子正相高效液相色谱（HPLC）为脂质提供了优越的分离选择性，这些脂质在脂肪酸链中双键的数量和位置上存在差异，包括在优化条件下对甘油三酯（TG）位置异构体的分辨。我们的银离子HPLC方法是基于三根总长度为75厘米的柱子耦合以及一个新的由己烷、乙腈和丙酮醇组成的移动相梯度，这相比于之前使用的移动相提供了更好的分辨率和重复性。在我们的工作中，利用单酸TG标准的化学酯交换（随机化）来生成TG的位置异构体系列，因为这可以在明确定义的浓度比下提供脂肪酸在TG中的随机分布。首次报道了含有最多三个双键的位置异构体TG对的基线分离以及含有四到七个双键的TG位置异构体的部分分离。我们的银离子高效液相色谱/质谱（HPLC/MS）方法应用于植物油和动物脂肪的复杂样品的位置异构体特性鉴定，结果清楚地展示了在植物（主要是不饱和脂肪酸）和动物脂肪（主要是饱和脂肪酸）中sn-2占位偏好的不同。

  DOI：

  10.1021/ac900150j

文献信息

• Resin, composition and use
  申请人：DSM IP ASSETS B.V.

  公开号：US10442955B2

  公开（公告）日：2019-10-15

  Low VOC, unsaturated alkyd resins are obtained by reacting (A) to (E): (A) optionally from 0 to 30% w/w naturally occurring Rosin, comprising from 40 to 80 w/w parts per hundred of Rosin of an unsaturated mono carboxylic acid with at least one C15-25cyclohydrocarbo moiety capable of a Diels Alder or Ene reaction (preferred monoacids being abietic acid, palustric acid, levopimaric acid, sandaracopimaric acid, and/or anhydrides thereof); (B) from 25 to 80% w/w of a linear C12-60hydrocarbo carboxylic acid with at least one (preferably at least two conjugated) C═C bonds (=unsaturated fatty acid); (C) optionally from 1 to 30% w/w of an ethylenically unsaturated C5-6hydrocarbo dicarboxylic acid and/or anhydride thereof, being reactive as a dienophile and/or enophile with A and/or B (preferred for C are itaconic acid, citraconic acid and/or anhydrides thereof); (D) from 1 to 40% w/w of at least one polyol; (E) optionally at least one monomer other than A to D—the total of A to E being 100%. There is a further optional step (II) where more or new (C) may be blended with the alkyd resin; the amount of C in blend being from 1 to 30 parts w/w of 100 parts of monomers (A) to (E)—and where (C) is at least used as a monomer and/or as a diluent in the blend and where alkyd resin (i) has acid value of <50 KOH/g of alkyd; (ii) Mn of >=1200 g/mol (iii) oil length <80; (iv) optionally biorenewable content >=50%.

  将(A)至(E)反应可获得低挥发性有机化合物的不饱和醇酸树脂：(A) 0% 至 30% w/w 的天然松香，其中包括 40% 至 80% w/w 的不饱和一元羧酸（松香中至少有一个 C15-25 环氢羧基能够发生 Diels Alder 或 Ene 反应）（优选的一元酸为阿比特酸、棕榈酸、左旋庚二酸、沙拉庚二酸和/或其酸酐）；(B) 25% 至 80% w/w 的线性 C12-60 羧酸，至少有一个（最好至少有两个共轭）C═C 键（=不饱和脂肪酸）；(C) 1-30%重量比的乙烯不饱和 C5-6 氢羧酸和/或其酸酐，作为亲二烯和/或亲 烯物与 A 和/或 B 反应（C 的优选物为衣康酸、柠康酸和/或其酸酐）； (D) 1-40%重量比的至少一种多元醇； (E) 除 A 至 D 之外的至少一种单体--A 至 E 的总和为 100%。还有一个可选步骤 (II)，在该步骤中，可将更多或新的 (C) 与醇酸树脂混合；C 在混合物中的用量为 100 份单体 (A) 至 (E) 中的 1 至 30 份 w/w，其中 (C) 至少用作混合物中的单体和/或稀释剂，醇酸树脂 (i) 酸值 =1200 g/mol (iii) 油长 =50%。
• Treatment of Respiratory Disorders
  申请人：Caparros-Wanderley Wilson

  公开号：US20130178448A1

  公开（公告）日：2013-07-11

  This invention relates to the treatment of respiratory disorders, and in particular respiratory disorders and oedema caused by pathogenic infections. In particular, the invention relates to orally administrable pharmaceutical compositions for treating respiratory disorders, and to methods of such treatment. The invention is particularly concerned with the treatment of respiratory disorders that are caused by viral infections, such as with influenza viral strains. The invention also extends to analgesic compositions and methods for treating inflammatory pain manifesting in a variety of diseases, and not only respiratory diseases.
• RESIN, COMPOSITION AND USE
  申请人：DSM IP ASSETS B.V.

  公开号：US20150111051A1

  公开（公告）日：2015-04-23

  There is described a low VOC, unsaturated alkyd resin obtained by reacting (A) to (E): (A) optionally from 0 to 30% w/w naturally occurring Rosin, comprising from 40 to 80 w/w parts per hundred of Rosin of an unsaturated mono carboxylic acid with at least one C 15-25 cyclohydrocarbo moiety capable of a Diels Alder or Ene reaction (pref monoacids being abietic acid, palustric acid, levopimaric acid, sandaracopimaric acid, and/or anhydrides thereof); (B) from 25 to 80% w/w of a linear C 12-60 hydrocarbo carboxylic acid with at least one (preferably at least two conjugated) C═C bonds (=unsaturated fatty acid); (C) optionally from 1 to 30% w/w of an ethylenically unsaturated C 5-6 hydrocarbo dicarboxylic acid and/or anhydride thereof, being reactive as a dienophile and/or enophile with A and/or B (pref C are itaconic acid, citraconic acid and/or anhydrides thereof); (D) from 1 to 40% w/w of at least one polyol; (E) optionally at least one monomer other than A to D—the total of A to E being 100%. There is a further optional step (II) where more or new (C) may be blended with the alkyd resin; the amount of C in blend being from 1 to 30 parts w/w of 100 parts of monomers (A) to (E)—and where (C) is at least used as a monomer and/or as a diluent in the blend and where alkyd resin (i) has acid value of <50 KOH/g of alkyd; (ii) Mn of >=1200 g/mol (iii) oil length <80; (iv) optionally biorenewable content >=50%.
• US9902870B2
  申请人：——

  公开号：US9902870B2

  公开（公告）日：2018-02-27
• [EN] TREATMENT OF RESPIRATORY DISORDERS<br/>[FR] TRAITEMENT DE TROUBLES RESPIRATOIRES
  申请人：BIOCOPEA LTD

  公开号：WO2011095814A1

  公开（公告）日：2011-08-11

  This invention relates to the treatment of respiratory disorders, and in particular respiratory disorders and oedema caused by pathogenic infections. In particular, the invention relates to orally administrable pharmaceutical compositions for treating respiratory disorders, and to methods of such treatment. The invention is particularly concerned with the treatment of respiratory disorders that are caused by viral infections, such as with influenza viral strains. The invention also extends to analgesic compositions and methods for treating inflammatory pain manifesting in a variety of diseases, and not only respiratory diseases.